Research programme: Mesd therapeutics - Horizon Pharma

Drug Profile

Research programme: Mesd therapeutics - Horizon Pharma

Alternative Names: WntTide

Latest Information Update: 14 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Washington University
  • Developer Raptor Pharmaceutical Corp; Washington University
  • Class Proteins
  • Mechanism of Action Wnt protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Discontinued Breast cancer; Osteoporosis

Most Recent Events

  • 12 Aug 2014 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
  • 12 Aug 2014 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
  • 01 Mar 2010 Pharmacodynamics and adverse events data from a preclinical study in Breast cancer released by Raptor Pharmaceuticals ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top